• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Masimo Shares Look Healthy Enough to Continue Their Run Higher

The stock of the maker of patient monitoring equipment has been in an uptrend the past year and its charts indicate it could rise even more.
By BRUCE KAMICH
Jan 29, 2020 | 08:16 AM EST
Stocks quotes in this article: MASI

For the Executive Decision segment of "Mad Money" Tuesday, Jim Cramer spoke with Joe Kiani, chairman and CEO of Masimo Corp. (MASI) , a global medical technology company that makes noninvasive patient monitoring equipment, medical devices and a wide array of sensors.

Jim and Joe discussed the battle brewing over health data privacy and electronic medical records. Kiani noted that patients are harmed when doctors and hospitals don't have all the information they need to diagnose and treat the problem. Let's check out the charts of MASI.

In this daily bar chart of MASI, below, we can see that prices have been in an uptrend the past year. Prices have made a number of corrections and pullbacks along the way. We can see a successful test of the rising 200-day moving average line in April and another one in November. MASI is above the rising 50-day moving average line and we can see that the On-Balance-Volume (OBV) line has also been positive for much of the past year. A rising OBV line is a sign that buyers of a stock have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator has moved widely around the zero line the past year because of the periodic corrections in the stock price. The indicator currently is above the zero line but crossing to a take profits sell signal.

In this weekly bar chart of MASI, below, we can see that prices have doubled in the past two years after a base pattern in the $80 area. Prices are above the rising 40-week moving average line and we can see a number of successful tests of the line in the past two years. The weekly OBV line shows a slow but steady rise the past three years to support the uptrend and the MACD oscillator is bullish on this longer time frame.

In this daily Point and Figure chart of MASI, below, we can see that the software has projected a potential upside price target in the $190 area. A move to the round number of $200 should not be ruled out.

Bottom line strategy: As someone who underwent major surgery last year and acted as a caregiver to my wife after surgery two years ago, I understand some of the issues and problems with health data privacy. It's not black and white. The uptrend in the stock is easier to discuss. Traders could play MASI from the long side around $170, risking below $160 while looking for gains to $190 and maybe $200.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Health Care Equipment & Services | Healthcare | Technology | Mad Money | Executive Interview | Real Money

More from Stocks

Don't Shout 'V' for Victory, Yet

James "Rev Shark" DePorre
Jun 27, 2022 4:22 PM EDT

Even after last week's move higher and Monday's narrow range of movement, we can say it's going to be difficult to produce a 'V'-shaped setup like we had at the pandemic low in 2020.

Let's See If Vertex Pharmaceuticals Can Push Higher on the Charts

Bruce Kamich
Jun 27, 2022 3:03 PM EDT

Here's what traders should do.

LyondellBasell Could Hold Temporarily Before Renewed Declines

Bruce Kamich
Jun 27, 2022 2:22 PM EDT

Let's take a look.

Kass: Why Markets Could Make a Yankees-Like Comeback

Doug Kass
Jun 27, 2022 2:00 PM EDT

I remain uncharacteristically bullish. Here's why.

If You Buy Now in This Bear-Bull Battle, You May Be Paying Later

Bob Lang
Jun 27, 2022 1:00 PM EDT

You really want to snag a bargain -- and bank a win -- right now. Here's a better strategy.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login